索引于
  • 打开 J 门
  • 学术钥匙
  • 研究圣经
  • 中国知网(CNKI)
  • 国际农业与生物科学中心 (CABI)
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-WorldCat
  • CABI 全文
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 谷歌学术
分享此页面
期刊传单
Flyer image

抽象的

Favipiravir: Promising Therapy for COVID-19

Amit Kumar Das*

COVID 19 is become one of the most threatened pandemics in recent time and spreading rapidly. Favipiravir, an antiviral drug, has shown promising but yet unproven effect against COVID-19 infection. Drug Controller General of India (DCGI) has recently approved Favipiravir for treating moderate to severe COVID-19 infected patients. Favipiravir, a broad-spectrum antiviral drug that interferes with the viral replication and emerging as promising therapeutic potential as indicated by initial clinical studies. In this literature review author tries to summaries an overview of Favipiravir as a promising therapy for COVID-19 disease.